Market Place
Sourcing Support
Antibe Announces Appointment of Receiver
24 Apr 2024 //
BUSINESSWIRE
Antibe Provides Update on CCAA Proceedings
19 Apr 2024 //
BUSINESSWIRE
Antibe Announces TSX Delisting Review
16 Apr 2024 //
BUSINESSWIRE
Antibe Receives Initial Order Under Creditors` Arrangement Act
10 Apr 2024 //
BUSINESSWIRE
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
02 Apr 2024 //
FINANCIAL TIMES
Antibe to Present Otenaproxesul PK/PD Results at Meeting
07 Mar 2024 //
BUSINESSWIRE
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
04 Mar 2024 //
BUSINESSWIRE
Antibe Reports Q3 2024 Interim Financial and Operating Results
14 Feb 2024 //
BUSINESSWIRE
Antibe Extends Early Warrant Exercise Incentive Program
01 Feb 2024 //
BUSINESSWIRE
Antibe Therapeutics Announces Amendment to Warrant Terms
12 Dec 2023 //
BUSINESSWIRE
Antibe Reports PK Results of First Study of Otenaproxesul’s New Formulation
09 Nov 2023 //
BUSINESSWIRE
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
01 Nov 2023 //
BUSINESSWIRE
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
18 Oct 2023 //
BUSINESSWIRE
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
28 Sep 2023 //
BUSINESSWIRE
Antibe Announces Results of 2023 Annual Meeting
08 Sep 2023 //
BUSINESSWIRE
Antibe Reports 2023 Year-End Results and Business Highlights
29 Jun 2023 //
BUSINESSWIRE
Antibe’s Chief Medical Officer to Present at the 2023 in Clinical Trials Summit
25 Apr 2023 //
BUSINESSWIRE
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
18 Apr 2023 //
BUSINESSWIRE
Antibe Provides April 2023 Corporate Update
11 Apr 2023 //
BUSINESSWIRE
Antibe Reports Q3 2023 Interim Financial and Operating Results
15 Feb 2023 //
BUSINESSWIRE
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
02 Nov 2022 //
BUSINESSWIRE
Antibe Provides Development Update for Otenaproxesul
12 Oct 2022 //
BUSINESSWIRE
Antibe Announces Results of 2022 Annual Meeting
09 Sep 2022 //
BUSINESSWIRE
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
06 Sep 2022 //
BUSINESSWIRE
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
15 Aug 2022 //
BUSINESSWIRE
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
30 Jun 2022 //
BUSINESSWIRE
Antibe Therapeutics Announces Amendment to Warrant Terms
15 Jun 2022 //
BUSINESSWIRE
Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
25 May 2022 //
BUSINESSWIRE
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
02 May 2022 //
BUSINESSWIRE
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
14 Feb 2022 //
BUSINESSWIRE
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
16 Nov 2021 //
BUSINESSWIRE
Antibe Therapeutics Outlines Plan for Otenaproxesul`s Acute Pain Program
01 Nov 2021 //
BUSINESSWIRE
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
14 Oct 2021 //
BUSINESSWIRE
Antibe Therapeutics to Present at H.C. Wainwright 23rd Annual Conference
08 Sep 2021 //
BUSINESSWIRE
Antibe Therapeutics Announces Results of 2021 Annual Meeting
19 Aug 2021 //
BUSINESSWIRE
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
17 Aug 2021 //
BUSINESSWIRE
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Conference
09 Aug 2021 //
BUSINESSWIRE
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
04 Aug 2021 //
BUSINESSWIRE
Antibe Therapeutics Provides July 2021 Corporate Update
27 Jul 2021 //
PR NEWSWIRE
Antibe Therapeutics Collaborates With Dalriada Drug Discovery
26 Jun 2021 //
BUSINESSWIRE
Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
07 Jun 2021 //
BUSINESSWIRE
Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
07 May 2021 //
BIOSPACE
Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
06 May 2021 //
BUSINESSWIRE
Antibe Therapeutics Receives FDA Clearance of IND Application
29 Mar 2021 //
BUSINESSWIRE
Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul
29 Mar 2021 //
BUSINESSWIRE
Antibe Therapeutics inks licensing deal with Nuance Pharma
15 Feb 2021 //
BIOSPECTRUMASIA
Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance
09 Feb 2021 //
BUSINESSWIRE
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics
09 Feb 2021 //
PRNEWSWIRE
Antibe Strengthens Partnering Advisory Team With Appointment
08 Jan 2021 //
BUSINESSWIRE
Antibe Therapeutics Announces Intent to Unify Intellectual Property Ownership
18 Dec 2020 //
BUSINESSWIRE
Antibe Announces TSX Approval and Effective Date of Share Consolidation
30 Nov 2020 //
BUSINESSWIRE
Antibe Therapeutics Announces TSX Approval and Effective Date of Share
29 Nov 2020 //
BUSINESSWIRE
Antibe Announces TSX Approval and Effective Date of Share Consolidation
29 Nov 2020 //
BUSINESSWIRE
Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise
24 Nov 2020 //
BUSINESSWIRE
Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise
24 Nov 2020 //
BUSINESSWIRE
Antibe Therapeutics to Complete Share Consolidation for Potential NASDAQ Listing
17 Nov 2020 //
BUSINESSWIRE
Antibe Therapeutics Engages Stern IR for Investor Relations Services
07 Aug 2020 //
BUSINESSWIRE
Antibe Therapeutics Engages Stern IR for Investor Relations Services
06 Aug 2020 //
BIOSPACE
Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering
09 Jun 2020 //
BUSINESSWIRE
Antibe`s NSAID alternative curbs arthritis pain in phase 2
01 Jun 2020 //
FIERCE BIOTECH
